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Variceal Bleeding from Cirrhosis: A Clinical Review of Causes and 
Pharmacotherapy Options
by Hillary Aphaisuwan, Pharm.D. Candidate, Midwestern University College of Pharmacy-Glendale  Class of 2014, Ibrahim Lala, 
Pharm.D. Candidate Midwestern University College of Pharmacy-Glendale  Class of 2014, and Laura Tsu, Pharm.D., BCPS, 
Assistant Professor, Pharmacy Practice, Midwestern University College of Pharmacy-Glendale
Goal:
This home-study CPE activity has been 
developed to educate pharmacists on the 
prevention and treatment of hemorrhagic 
esophageal varices resulting from 
cirrhosis.
Objectives:
At the conclusion of this lesson, successful 
participants should be able to:
1. Explain which systemic complications 
are commonly seen in cirrhotic 
patients
2. Compare the mechanism of action of 
the medications used to prevent and 
treat hemorrhagic varices
3. Select an appropriate dose of 
medication for the prevention and 
treatment of hemorrhagic varices
4. Formulate an appropriate therapeutic 
regimen for a patient given the current 
state of the varices
Introduction:
Epidemiology and Etiology
Cirrhosis is an irreversible, chronic liver 
disease which affects slightly more than 
100,000 individuals and caused 31,000 
deaths in 2009.1  This represents a 30% 
mortality rate, which is significantly 
higher than more prevalent disease 
states.  The high rate of death due to 
cirrhosis indicates the importance of 
pharmacotherapeutic interventions, which 
can readily prevent complications and 
reduce mortality.  Educating pharmacists 
on proper treatment options allows them 
make recommendations and ensure that 
patients are receiving optimal therapy 
based on the most current evidence 
available.
There are multiple etiologies of 
cirrhosis, including metabolic diseases, 
autoimmune diseases, and non-alcoholic 
fatty liver disease/non-alcoholic 
steatohepatitis.  The most common causes, 
however, are chronic alcohol abuse 
(defined as two to three drinks per day 
for women, and three to four drinks per 
day for men) and chronic infection with 
Hepatitis B, C or D viruses.2,3  In addition, 
certain medications can lead to cirrhosis 
due to hepatotoxicity, the most commonly 
used of which is acetaminophen.4
Pathophysiology
Cirrhosis is characterized histologically 
by the presence of fibrotic lesions in 
the liver.  Due to chronic offense to the 
liver, inflammation and tissue injury 
persist.  Abnormal wound healing leads 
to the replacement of normal hepatocytes 
with collagenous scar tissue, which can 
then be encapsulated by a fibrotic cap.  
Eventually, the fibrosis accumulates to 
such a degree that the scar tissue disrupts 
hepatic vasculature, compromising hepatic 
circulation and resulting in a reduction of 
liver function.  Once hepatic circulation is 
compromised and vasculature is damaged, 
liver fibrosis is classified as cirrhosis.  
The end result of this excess fibrosis is 
poor liver function, increased intrahepatic 
resistance (leading to portal hypertension), 
and an increased risk for the development 
of hepatocellular carcinoma.3,5
Signs and Symptoms
Signs and symptoms of cirrhosis vary 
widely, depending on the degree of liver 
damage that has occurred.  Typically, 
early damage shows few unique signs 
and symptoms, and as a result goes 
undetected and undiagnosed.  Symptoms 
of nonspecific liver damage, which may 
present in the early stage of cirrhosis, 
include jaundice, bleeding and bruising, 
fatigue, and nausea.3,6,7  As cirrhosis 
progresses, the signs and symptoms 
become progressively more serious.  
These systemic complications are often 
the reason a patient gets evaluated and 
diagnosed in the first place.  Advanced 
cirrhotic patients present with the hallmark 
systemic complications described below.  
In addition to the described signs 
and symptoms, certain lab findings are 
consistent with cirrhosis.  In both the early 
and advanced stages of cirrhosis, a patient 
may present with elevated liver enzymes 
(with AST > ALT), elevated bilirubin, 
hypoalbunemia, thrombocytopenia, and 
leukopenia.3,7  As with external signs 
and symptoms, these laboratory findings 
progress as the disease progresses, and 
may not become apparent until a patient 
has a more advanced case of the disease.  
Systemic Complications
Stemming from the vascular changes 
and the resultant increase in intrahepatic 
resistance, cirrhosis results in systemic 
complications.  These complications 
include: portal hypertension, esophageal 
varices, ascites, spontaneous bacterial 
peritonitis (SBP), hepatic encephalopathy, 
hepatorenal syndrome, and 
coagulopathies.  
The primary complication, nearly 
universal among cirrhotic patients, is 
portal hypertension.  It is defined as an 
increased resistance to hepatic circulation.  
Due to altered morphology of the liver 
caused by fibrosis, the liver is unable to 
efficiently circulate blood through the 
portal vein, hepatic sinusoids, and in 
hepatic venous outflow.  Quantitatively, 
portal hypertension is defined as a pressure 
gradient between the portal and central 
veins of more than 5mmHg.  This gradient 
is called the hepatic venous pressure 
gradient (HVPG).3,5
A primary consequence of portal 
hypertension is the development of 
varices.  Due to an increase in portal 
resistance, blood flow backs up into the 
left gastric vein, which drains much of the 
blood leaving the esophagus.  As a result 
of back-up, the left gastic vein and its 
tributaries become dilated.  These swollen 
esophageal veins are called varices, which 
are prone to twisting and rupture, leading 
to internal hemorrhage.  Qualitatively, 
hemorrhagic varices typically present 
as hematemesis and abdominal pain.  
Quantitatively, varices develop when the 
HVPG rises to 8 - 10mmHg.  When the 
HVPG further rises to >12mmHg, these 
varices can rupture, resulting in variceal 
bleeding into the abdomen.  Variceal 
bleeding occurs in up to 40% of cirrhotic 
patients, and has a 33% fatality rate.3,5
In addition to causing varices, portal 
hypertension results in ascites, which 
is the accumulation of fluid within the 
peritoneal cavity.  Ascites occurs in 
approximately 50% of cirrhotic patients.  
It is a result of three factors: persistent 
water retention (due to a drop in arterial 
blood pressure), increased splanchnic 
vascular permeability (due to persistent 
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vasodilation as a result of intrahepatic 
resistance) and lymph leakage into the 
peritoneum.3,5
Another common, and often fatal, 
complication of cirrhosis is spontaneous 
bacterial peritonitis (SBP).  In cirrhotic 
patients, enteric bacteria undergo bacterial 
translocation into abdominal lymph nodes. 
When cirrhotic patients become ascitic, 
these bacteria move along with lymphatic 
fluid into the peritoneum, resulting in 
SBP.8  In the presence of ascites, patients 
are often treated prophylactically to 
prevent SBP.  The American Association 
for the Study of Liver Diseases (AASLD) 
guidelines recommend treating patients 
prophylactically for SBP when they 
present with hemorrhagic varices, as 
studies have shown that this reduces 
infectious complications and reduces 
mortality.9,10
Hepatic encephalopathy (HE) is the 
result of the liver's inability to process 
nitrogenous wastes, resulting in an 
increased ammonia load in the blood.  
These wastes can enter the CNS, altering 
neurotransmission and resulting in an 
altered mental status, typically confusion.  
While HE does not correlate directly with 
a specific blood ammonia level, treatments 
focus on removal of ammonia from the 
blood.3
As a result of splanchnic vasodilation, 
there is decreased renal blood flow, and 
thus, a decreased glomerular filtration 
rate.  These factors present as hepatorenal 
syndrome, which is functional renal 
failure in the absence of renal disease.  
Hepatorenal syndrome occurs in about 
20% of patients within 1 year of being 
diagnosed, and approximately 40% of 
patients after 5 years.11
The last commonly seen systemic 
complication of cirrhosis is a set of 
coagulopathies.  Due to the fact that 
the liver is responsible for producing 
the proteins responsible for hemostasis, 
damage to the liver disrupts this delicate 
balance.  Hemostatic substances, such as 
clotting factors and platelets, are decreased 
in cirrhotic patients.  The net result of this 
hemostatic disruption is the development 
of bleeding, which results in an elevated 
prothrombin time.3
Classification of Cirrhosis and Varices
The Child-Pugh scoring system is a 
numerical measurement of the severity 
of a patient's cirrhosis.  It takes into 
account whether the patient has ascites, 
the patient's bilirubin level, serum 
albumin, prothrombin time, and whether 
encephalopathy is present.  Based on the 
patient's lab values and the severity of 
encephalopathy and ascites (if present), 
point values are assigned to each 
characteristic.  The points are then added 
up, and the patient is then classified as 
Child A, B, or C, in order of increasing 
severity of cirrhosis.  See Table 1 for 
the numerical scores assigned to each 
characteristic.12  A Child A patient has 
a 100% 1-year survival rate, whereas a 
Child C patient only has a 40% 1-year 
survival rate.3
Varices are categorized based on 
their appearance and size.  Per AASLD 
guidelines, varices should be classified 
into one of two categories: small or large.  
Small varices are those that are <5mm in 
diameter, while large varices are those that 
are >5mm in diameter.  Some institutions 
utilize a three category classification based 
on morphological assessment.  In these 
institutions, small varices are minimally 
elevated above the lumen, medium varices 
are torutous veins occupying less than 
one-third of the esophageal lumen, and 
large varices occupy more than one-
third of the esophageal lumen.  AASLD 
guidelines recommend treating medium 
varices the same as large varices.10
A combination of the Child-Pugh score 
and variceal categorization is used to 
determine the treatment for varices, as 
described below.
Variceal Management:
There are three main components to 
management of variceal hemorrhages: 
prevention of first incident of bleeding, 
treatment of acute variceal hemorrhages, 
and prevention of rebleeding.  It is 
recommended that all patients undergo 
esophagogastroduodenoscopy (EGD) 
regularly to screen for the presences 
of varices.  The AASLD guidelines 
recommends an EGD every three years 
if no diagnosis of varices is made upon 
initial examination.  After a diagnosis of 
varices is made, preventive measures of 
variceal hemorrhages are dependent on the 
patient’s Child-Pugh Score.13
Prevention of Variceal Hemmorhages
Patients with Small Varices
AASLD guidelines state that patients 
with small varices that have not bled who 
have a Child-Pugh score of B/C should 
use nonselective β-blockers (NSBB), 
such as propranolol or nadolol, for the 
prevention of a first variceal bleeding 
event.  These agents can also be used 
for patients with no increased risk of 
bleeding but benefits are inconclusive.13  
NSBB can significantly reduce the risk 
of bleeding by reducing portal pressure 
by two mechanisms.  These medications 
can decrease cardiac output by blocking 
adrenergic β1 receptors and reduce 
portal blood flow through splanchnic 
vasoconstriction by blocking adrenergic 
β2 receptors.  For this reason, NSBB must 
be used over selective beta-blockers in the 
case of primary prophylaxis.  According 
to the AASLD guidelines, propranolol 20 
mg orally twice daily or nadolol 40 mg 
orally once daily can be given.  Doses of 
these agents are titrated to decrease the 
heart rate 25% from baseline.  However, 
Role of the Pharmacist and Conclusion: 
 
In a community setting, pharmacists may deal with long-term management of cirrhosis and prevention 
of exacerbations. While the acute complications, such as variceal hemorrhage, can be fatal, proper 
long-term management of the disease state is essential to prevent those acute complications from 
occurring. Patients with cirrhosis may be on many medications concomitantly, and the pharmacist 
should always screen for drug-drug interactions. It would not be uncommon to see an advanced stage 
cirrhosis patient on a beta-blocker for variceal management, a loop diuretic for ascites prevention, and 
warfarin for coagulopathy management. When combined with medications for other disease states, it is 
easy to see where medication therapy management can have a large impact and optimize outcomes. 
 
In an acute care setting, pharmacists can also have a large impact. The acute management of variceal 
hemorrhage is a complicated one involving many medications and procedures. The pharmacist can 
ensure that proper antibiotics are being selected, and assist in the management of adverse effects from 
the myriad medications that a patient will be on while in the hospital.  
 
Overall, cirrhosis is a dangerous disease state with a high mortality rate. There are a host of systemic 
complications that can arise as a result, and the acute and chronic management of these complications 
are essential in improving quality of life and preventing morbidity and mortality. The most commonly 
seen complication is an acute variceal hemorrhage, which has a complicated, but well-defined 
treatment protocol involving vasoactive agents, beta-blockers, antimicrobials and surgical procedures. 
A last line-treatment option when complications cannot be managed is a liver transplant. 
 
Table 1 – Child-Pugh Classification of Cirrhosis10  
 
Table 2 – Primary Prophylaxis of Variceal Bleeding 
   
 Child-Pugh Class A Child-Pugh Class B or C 
Small Varices Annual upper endoscopy Initiate NSBB therapy 
Medium or 
Large Varices N/A 
Initiate NSBB therapy or treat with endoscopic 
ligation (EBL/EVL) 
 
 

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reducing heart rate has not been found 
to reduce HVPG so maximal tolerated 
doses are commonly used.13,14  Heart rate 
and blood pressure should be monitored 
in patients on this medication.  Patients 
should be cautioned against the side 
effects of NSBB which include, but are 
not limited to syncope, fatigue, dizziness 
and impotence.15,16  Although direct 
comparison trials have not been completed 
with propranolol and nadolol, propranolol 
showed higher rates of side effects13.  If 
patients are to discontinue their use of 
NSBB, the medication must be tapered 
over 2 weeks to avoid hypertension, acute 
tachycardia and/or ischemia.15,16  Patients 
receiving beta-blockers do not require an 
EGD but those who are not should obtain 
an EGD every 2 years.13
Patients with Medium/Large Varices
AASLD guidelines state that patients 
with medium/large varices that have 
not bled (Child-Pugh score of B/C) 
should receive NSBB.  The same 
recommendations can be considered 
in patients who are not at a high risk 
of bleeding.  Propranolol 20mg orally 
twice daily or nadolol 40 mg orally once 
daily can also be given to patients who 
fall under this category.  Monitoring 
parameters for safety and efficacy for 
these medications follow those described 
previously.13  Endoscopic variceal 
ligation (EVL) can also be used for 
patients with medium/large varices and 
has showed a small, significant lower 
incidence of bleeding in comparison to 
NSBB use.14  EVL involves the use of 
rubber bands attached to varices.  After 
48 - 72 hours, the varix will slough off 
and leave a mucosal ulceration that will 
heal.  The procedure is repeated every 
1 - 2 weeks until complete resolution of 
the varices.17  Repeat examinations are 
also recommended in 1 - 3 months, then 
every 6 - 12 months.  AASLD guidelines 
do not recommend the use of nitrates 
in the prevention of first event variceal 
hemorrhage.  Nitrates, such as isosorbide 
mononitrate, are effective in comparison 
to NSBB but were found to increase 
mortality rates in a long-term follow 
up study.  In addition, shunt therapy or 
sclerotherapy is also not recommended for 
use in primary prevention.13 
Treatment of Variceal Hemmorhages
The treatment of cirrhosis includes 
resolving acute complications that 
arise from the condition and preventing 
further ones from occurring.  Variceal 
hemorrhage is a dangerous complication 
of cirrhosis that warrants immediate 
treatment requiring general stabilization of 
the patient and controlling the bleeding.3 
According to the AASLD guidelines, 
the treatment of variceal hemorrhage 
include pharmacotherapy and endoscopic 
intervention.  Drug therapy typically 
includes a vasoactive agent to assist in the 
reduction of bleeding and an antibiotic 
to prevent SBP.  Endoscopic treatments 
such as sclerotherapy and variceal band 
litigation is also necessary to inhibit 
bleeding.13 
Acute Management of Variceal Bleeding
Variceal hemorrhage requires intensive 
care and hemodynamic stability of airway, 
breathing and circulation of the patient.  
Goals of treatment include systolic 
blood pressure of 90-100 mmHg, heart 
rate less than 100 beats per minute, and 
a stabilization of blood volume for a 
target hemoglobin level of 7-8 g/dL.  In 
addition, a transfusion of fresh frozen 
plasma and platelets can be given for 
severe coagulopathy or thrombocytopenia 
Excessive fluids are typically avoided 
to prevent complications of ascites.  
Recombinant factor VIIa is also not 
recommended.3, 14
Vasoactive Drug Therapy
Common vasoactive medications used 
for the treatment of variceal hemorrhages 
include octreotide and vasopressin.3  
Octreotide is a splachnic vasoconstrictor 
that assists in the reduction of portal blood 
flow and pressure.  This agent works by 
inhibiting vasodilatory agents in the body 
with effects localized to the splanchnic 
vasculature, causing fewer side effects 
than vasopressin.  Although octreotide is 
available as subcutaneous and intravenous 
injections, it is recommended to be 
used intravenously for this treatment.  
The recommended dose for the use of 
octreotide is a 50 mcg bolus followed 
by 50 mcg/hr continuous infusion.  The 
guidelines recommend continuing the use 
of octreotide for 5 days after an incident 
of variceal hemorrhaging to prevent 
the reoccurrence of bleeding, since this 
complication commonly occurs 3 - 5 
days after an initial incident.13,14  Patients 
on octreotide should be monitored for 
safety for dyspnea, hypothyroidism, 
cardiovascular issues, GI disturbances and 
CNS changes.  It should also be used in 
caution with patients currently on insulin 
therapy for hyper/hypoglycemia.  Patients 
should also be educated on side effects 
of dyspepsia, flatulence, nausea, and 
headache.18 
Vasopressin (also known as 
antidiuretic hormone) can also be used 
for the treatment of acute variceal 
hemorrhages.  This agent is also a 
splachnic vasoconstrictor that causes 
a reduction of portal blood flow and 
pressure, however, unlike octreotide, 
vasopressin is a nonselective agent so its 
effects are not localized to the splanchnic 
vasculature bed.  Because of its systemic 
effects, vasopressin can cause a reduction 
of cardiac output, heart rate and coronary 
blood flow which can cause further 
complications of myocardial infarction, 
arrthymias and other cardiovascular 
effects.  The recommended dose for 
vasopressin is a 0.2 - 0.4 unit/minute 
(maximum of 0.8 unit/minute) by 
continuous infusion for a maximum of 24 
hours.  It must be administered along with 
intravenous nitroglycerin (40 – 400 mcg/
minute adjusted to maintain SBP of over 
90 mmHg) to reduce the risk of adverse 
events.3,13,14  Serum and urine sodium, 
serum and urine osmolality, fluid input 
and output, blood pressure and heart rate 
should be monitored for safety in the use 
of vasopressin.19  Common side effects 
of vasopressin include nausea, vomiting, 
vertigo and chest pains.  The use of 
vasopressin is undesirable in comparison 
to octreotide due to its systemic side 
effects and risk for complications.  
Because of this, octreotide has been more 
commonly used for the treatment of acute 
variceal hemorrhage than vasopressin.13  
Terlipressin, a common agent used 
in Europe, is a synthetic analogue of 
vasopressin.  Although it is quite similar 
to vasopressin, it has a longer duration of 
action.  More importantly, terlipressin has 
fewer side effects compared to vasopressin 
and has a lower risk for serious 
complications.3  
Spontaneous bacterial peritonitis (SBP) 
is a serious complication that can arise 
due to an acute variceal hemorrhage.  
Active bleeding in patients can increase 
the risk of bacterial infections such as 
SBP.  As described previously, enteric 
bacteria undergo bacterial translocation 
into abdominal lymph nodes which 
can lead to SBP.  According to AASLD 
guidelines, all patients should receive 
Continuing EduCation (ContinuEd from pagE 40)
Summer 2013 • ArizonA JournAl of PhArmAcy • 41
a short course of antibiotic therapy to 
reduce these risks.  Antibiotic therapy 
can also prevent bleeding reoccurrences 
and decrease mortality in cirrhosis 
patients.  Common pathogens of SBP 
include Escherichia coli, Klebsiella 
pneumoniae, Streptococcus pneumoniae, 
and Enterococcus species.  Over 90% 
of these cases are monomicrobrial and 
most are caused by E.  coli and Klebsiella 
sp.3, 13, 20, 21  Norfloxacin 400mg BID 
can be used for oral administration of 
antibiotic prophylaxis to cover E. coli, K 
pneumonia, S. pneumonia over a course 
of 7 days maximum.  Norfloxacin should 
be taken on an empty stomach either 
one hour before or two hours after meal.  
Adequate hydration is also recommended 
in norfloxacin use.  Patients should 
be informed of common side effects 
including dizziness, lightheadedness, 
headache, nausea, vomiting and 
photosensitivity.  Patients on norfloxacin 
should also be monitored for tendon 
inflammation or pain.21  For prolonged 
therapy, CBC, renal and hepatic function 
must be monitored.  If oral administration 
is contraindicated, ceftriaxone 1g/day or 
ciprofloxacin IV can be used.
Endoscopic Interventions
Endoscopy should be performed as 
soon as possible to inhibit active variceal 
bleeding.  Although endoscopy is used to 
diagnose the variceal bleeding, it can also 
be used to assist in the inhibition of active 
hemorrhaging.  EVL, as described above, 
can be completed in the event of active 
variceal hemorrhage and the procedure 
is repeated in 7 - 10 days to ensure 
complete resolution of the varices.  Repeat 
examinations are also recommended in 
one month, then every three months, after 
the procedure.13, 17 
Endoscopic sclerotherapy involves the 
injection of a sclerosing agent to cause 
thrombosis of varices and subsequently 
inhibit blood flow.  There are many 
sclerosing agents that can be used and 
none have been proven to be superior over 
another agent.  Commonly, 1 - 2 mL of 5% 
sodium morrhuate per injection for a total 
of 12 - 20 mL per session has been used.  
Ethanolamine is an alternative sclerosing 
agent using the same dosing regimen.  
In regard to endoscopic interventions, 
sclerotherapy has shown inferiority over 
EVL and should be used in the treatment 
of variceal hemorrhages.  In comparison to 
EVL, endoscopic sclerotherapy can result 
in less control of the hemorrhage, higher 
risks of adverse events and higher risks for 
rebleeding occurrences.3,13
Alternative Treatments
In the case of failure from previous 
treatments, balloon tamponade can 
be used.  Although this method can 
assist in the short-term treatment of 
variceal hemorrhage, it can lead to 
further complications and a high risk of 
rebleeding.13  The Sengstaken-Blakemore 
tube, the Minnesota tube, and the Linton-
Nachlas tube have been used to stop 
variceal bleeding.  Surgery can also 
be used to control variceal bleeding in 
the failure of other treatments.  Two 
types of procedures exist for surgical 
options: shunt and nonshunt procedures.  
A common surgical procedure for the 
treatment of variceal hemorrhage includes 
a transjugular intrahepatic portosystemic 
shunt (TIPS) which involves the widening 
of a portal vein branch and a hepatic vein 
stent with a cylindrical wire mesh.  This 
allows the blood to bypass high pressure 
vessels which subsequently decreases 
pressure in the portal veins.23
Prevention of Rebleeding
In addition to treatment of an active 
variceal hemorrhage, it is also important 
to prevent bleeding reoccurrences in the 
future.  Rebleeding can occur in 60% of 
patients within 1 - 2 years after an initial 
complication and holds a 33% mortality 
rate.  Secondary prophylaxis does not 
have to be initiated in patients who have 
undergone shunt surgery for treatment.  
Patients with a Child-Pugh score equal to 
or greater than 7 should begin secondary 
prophylaxis for rebleeding.3  According 
to AASLD guidelines, the best option 
for secondary prophylaxis includes a 
combination of NSBB and EVL.  As in 
the prevention of first event bleeding, 
NSBB should be adjusted to a tolerated 
dose for each patient.  Also similar 
to first prophylaxis, EVL should be 
repeated every 1 - 2 weeks.  If EVL is 
contraindicated, the combination of NSBB 
and isosorbide mononitrate has shown 
slight benefits.  Guidelines also state that 
TIPS can be considered in patients with 
a Child-Pugh Score of A or B who have 
experienced an acute variceal hemorrhage 
on multiple occasions.  In the event of 
extreme situations and the failure of 
aforementioned treatments, liver transplant 
should be considered.13,14 
Role of the Pharmacist and Conclusion:
In a community setting, pharmacists 
may deal with long-term management of 
cirrhosis and prevention of exacerbations.  
While the acute complications, such 
as variceal hemorrhage, can be fatal, 
proper long-term management of the 
disease state is essential to prevent those 
acute complications from occurring.  
Patients with cirrhosis may be on many 
medications concomitantly, and the 
pharmacist should always screen for 
drug-drug interactions.  It would not be 
uncommon to see an advanced stage 
cirrhosis patient on a beta-blocker for 
variceal management, a loop diuretic 
for ascites prevention, and warfarin 
for coagulopathy management.  When 
combined with medications for other 
disease states, it is easy to see where 
medication therapy management can have 
a large impact and optimize outcomes.
In an acute care setting, pharmacists 
can also have a large impact.  The acute 
management of variceal hemorrhage 
is a complicated one involving many 
medications and procedures.  The 
pharmacist can ensure that proper 
antibiotics are being selected, and assist in 
the management of adverse effects from 
the myriad medications that a patient will 
be on while in the hospital.  
Overall, cirrhosis is a dangerous disease 
state with a high mortality rate.  There are 
a host of systemic complications that can 
arise as a result, and the acute and chronic 
management of these complications are 
essential in improving quality of life and 
preventing morbidity and mortality.  The 
most commonly seen complication is an 
acute variceal hemorrhage, which has a 
complicated, but well-defined treatment 
protocol involving vasoactive agents, 
beta-blockers, antimicrobials and surgical 
procedures.  A last line-treatment option 
when complications cannot be managed is 
a liver transplant.
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